The use of FSC in the regulation of menstrual function in women with opsomenorrhea

Danielyan T. Yu., gynecologist of the highest category, MD, head physician of Medical Studio LLC, Perm
Danielyan N. A., dermatovenereologist, Medical Studio LLC, Perm

Relevance of the problem. The menstrual cycle is a complex biological process provided by nature itself. Menstrual dysfunction and related hormonal problems are one of the main causes of gynecological morbidity.

In the second half of the 20th century, there was a significant revision of the role of women in society and the family, as well as changed views on her health. It is assumed that such changes in the function of the reproductive system, such as rare pregnancies, frequent abortions, lack of lactation, are accompanied by significant changes in hormonal status and explain the increase in the number of gynecological diseases such as menstrual dysfunction, adenomyosis, uterine fibroids, endometrial hyperplastic processes, etc.

In the structure of the general gynecological morbidity, menstrual irregularities range from 15 to 53%. Menstrual disorders are accompanied by infertility and changes in body weight, diseases of the mammary glands, the development of neuropsychiatric disorders, menopausal and cardiovascular changes, and the development of osteoporosis. Together, all these problems significantly affect the quality of life of a woman.

Recently, worldwide interest in the study of problems and the correction of menstrual dysfunction has increased significantly. The results of numerous studies indicate that in violation of the menstrual function, the main algorithm for the functioning of the reproductive system changes (violation of the cyclical secretion of sex hormones).

Prevention and treatment of menstrual disorders should begin at an early stage, before the formation of female hormone-dependent diseases.

Pharmacotherapy with steroid hormones is the main method of treatment in practical medicine and has an ambiguous effect on a woman's body. All this dictates the need to find effective and safe methods of treating menstrual dysfunction in women.

There is a solution, since at the present stage correctors of the functional state deserve special attention, having a complex effect on the most important organs and systems of the human body.

The purpose of the study.. Evaluation of the clinical efficacy of the combined effects of FSC in patients with menstrual dysfunction.

Object and methods of the study. To carry out the study, an "Observation Card" was developed, which included the criteria for inclusion in the study, general information about the patient, complaints and clinical symptoms, anamnesis data, criteria for diagnosing the disease , treatment regimen and indicators of clinical effectiveness of FSC.

The criterion for inclusion in the study was menstrual dysfunction in women of reproductive age according to the type of opsomenorrhea against the background of anovulatory menstrual cycles and luteal phase insufficiency.

In the process of observation, 63 patients were divided into two groups, depending on the methods of treatment used. In the main group (42 people), a complex course of basic therapy was prescribed with the inclusion of Correctors of the functional state (without the use of hormonal drugs). In the comparison group, patients (21 people) underwent drug hormone therapy.

In assessing the initial status and effectiveness of the treatment courses, the following research methods were used:

  • Relief of clinical symptoms
  • Ultrasound monitoring of the state of the endometrium and ovarian folliculogenesis on days 10-12 and 20-22 of the menstrual cycle (performed for the purpose of dynamic monitoring of the restoration of the echographic picture of the endometrium and the presence of a dominant follicle in the periovulatory period of the menstrual cycle)
  • Dynamics of changes in the parameters of the immunohistochemical study of the state of the endometrium (pipel test), performed on the 22-24th day of the menstrual cycle

The average age of the examined women was 28.4 +/- 2.5 years. The groups did not differ in major demographics, heredity, and physical status.

Complaints associated with menstrual disorders were observed in all women and did not differ significantly in groups.

Most often, patients complained of painful menstruation.

Violations of the duration of the menstrual cycle by day were different. Longer menstrual irregularities were recorded only in patients with anovulatory ovarian dysfunction.

Anovulatory ovarian dysfunction during initial monitoring was diagnosed in 11 (17%) women (5 people and 6 people in the 1st and 2nd groups, respectively)..

Insufficiency of the luteal phase of the ovarian cycle (hypoluteism) was observed in 52 (82.5%) women (37 people and 15 people in the 1st and 2nd groups, respectively).

According to the ultrasound data, all examined patients showed a violation of folliculogenesis in the ovaries and the absence of a dominant follicle in the periovulatory period.

Indicators of the immunohistochemical study of the endometrium showed the presence of only proliferative processes and a violation of the receptor apparatus of the endometrium on the 20-22nd day of the cycle in 54 (85.7%) women (37 people and 17 people in the 1st and 2nd groups, respectively ).

Methods of treatment:

  • Methodology for the use of FSC in women with menstrual dysfunction
  • Admission of FSC-structured water in the amount of 30 ml per 1 kg of body weight per day
  • Water procedures with FSC structured water
  • Restoring the energy state of the body by pumping the musculoskeletal system, energy centers of the body
  • Wear the FSC in a problematic place, periodically changing the location
  • FSC influence on biologically active points of the body (BAP)

Method of using FSC on biologically active points of the body (BAP). The effect of FSC on BAP was carried out taking into account the cyclic influence of the autonomic nervous system (ANS) on the regulation of the menstrual cycle. This technique consists in using tonic points, accomplice points, points of agreement and lo-points located on the yin meridians (yin) in the follicular phase of the menstrual cycle, and the use of BAP of the yang meridians (yang) in the luteal phase of the cycle. Local impact points were also used.

The procedure was performed from the 1st to the 14th day of the menstrual cycle using the BAP of the Yin meridians, from the 15th to the 28th day the BAP of the Yang meridians was used. The development of follicles was monitored by ultrasound, the dominant follicle was identified in order to diagnose the alleged or completed ovulation and the state of the endometrium.

Tab. 1. The use of FSC depending on the phase of the menstrual cycle and the time of day in case of menstrual dysfunction.

1st phase of the menstrual cycle2nd phase of the menstrual cycle
Up to 16..00FSC №1, 3, 5, 14,
FSC №1, 3, 5, 14,
After 4pmFSC №2, 3, 5, 8, 11,
FSC №2, 3, 5, 8, 11,

In case of ovarian dysfunction of central genesis by the type of anovulation with menstrual dysfunction by the type of opsomenorrhea, the following methods of using FSC are recommended:

  • FSC №2 - under the back of the head and FSC №3/8 - on the area between the eyebrows (5-10 minutes per day)
  • FSC №13/15 – on the area between the eyebrows
  • Pumping the "bonnet" using several FSCs of the "blue" series

Results. Evaluation of the clinical characteristics of the menstrual cycle and complaints made by patients 3 months after the start of therapy showed the following results.

  • Complaints of opsomenorrhea persisted in 15 patients (23.8% - 11 people and 4 people in the 1st and 2nd groups, respectively)
  • The regularity of the menstrual rhythm was noted by 48 women (76.1% - 32 people and 16 people in the 1st and 2nd groups, respectively), which demonstrates the comparable effectiveness of complex therapy with the inclusion of FSC in relation to this symptom, as well as advantage over drug therapy
  • All patients of the main group (with CFS) noted a subjective improvement, while in the comparison group, only 4 out of 21 patients noted an improvement, which indirectly reflects the greater potential for the effect of CFS on the general condition of the women's body
  • Reduction of pain during menstruation was noted by all patients of the main group and 15 patients of the comparison group (23.8%)

Dynamic ultrasound monitoring of the endometrium during observation and treatment revealed certain patterns. Initial monitoring showed similar disturbances in endometrial maturation in all groups before treatment.

A significant increase in the thickness of the endometrium in the proliferative phase of the cycle compared with baseline was noted after therapy already at the 3rd month of observation in patients of the main group. While drug therapy had no significant effect..

Assessment in the secretory phase of the cycle did not reveal significant positive dynamics in patients of the comparison group, while in patients of the main group a significant increase in endometrial parameters was recorded compared to the initial value.

A similar picture was observed in the main group of patients with menstrual dysfunction according to the type of opsomenorrhea, accompanied by anovulation. According to ultrasound data, dynamic folliculogenesis was noted with the appearance of a dominant follicle in the periovulatory period in 85.7% (36 out of 42 people) of patients in the main group. In the comparison group, this indicator was registered in 39% (8 out of 21) of patients.

A positive effect was observed in relation to the parameters of the immunohistochemical study of the endometrial biopsy: the presence of secretory changes in the luteal phase of the cycle and an increase in the endometrial receptor apparatus in 80.9% (34 out of 42) of patients in the main group with CFS. In the comparison group, secretory changes in the endometrium and an increase in the percentage of hormonal receptors were observed in 28.5% (6 out of 21).

Conclusion. The use of FSC in the treatment of correction of menstrual dysfunction by the type of opsomenorrhea is a highly effective addition to treatment and helps to avoid complications from drug polypharmacy with hormonal preparations.